Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone for patients with advanced non-small cell lung cancer and EGFR mutations: Phase 3 randomized clinical trial (Mexico). This evidence concerns the gene EGFR and non-small cell lung carcinoma.